News

EMUC20 and COVID-19

EMUC20 will be going to a virtual programme on 13 and 14 November. The meeting site is being updated accordingly. Previous updates: 19 June – The global pandemic has of course impacted many scientific events that were scheduled for...

12th EMUC celebrates longstanding ties between societies

The EAU, the European Society for Medical Oncology (ESMO) and the European SocieTy for Radiotherapy & Oncology (ESTRO) are making plans for EMUC20, the 12th European Multidisciplinary Congress on Urological Cancers. The congress is set to take place in...

Imaging and pathology: The harm of false positives

“A false positive can really change the life of a patient so we should only make a diagnosis if we are 100% certain,” said Prof. Harriet Thoeny (Bern, CH) at EMUC19 on Saturday. Prof. Thoeny was co-chairing a session...

ARAMIS likely to change Guidelines recommendations

The third day of the EMUC meeting (and the second day of the main scientific programme) opened with a two-hour session on new trials. Like all sessions at EMUC19, it was chaired by a multidisciplinary group, in this case...

HoT courses highlight MRI reading and fusion biopsy

Two Hands-on Training (HoT) courses organised by the European School of Urology (ESU) and the EAU Section of Urological Imaging (ESUI) simultaneously commenced on day 2 of the 11th European Multidisciplinary Congress on Urological Cancers (EMUC19). The ESU/ESUI Hands-on...

Early detection of prostate cancer: a multidisciplinary look

Using the fortieth anniversary of the discovery of PSA as a starting point, EMUC19 began with a session on early prostate cancer detection. The session immediately demonstrated the multidisciplinary nature of the EMUC scientific programme, drawing on the expertise...

Urine biomarkers may detect disease state in NMIBC

The Scientific Programme of the EMUC congress is well-known for its broad coverage of relevant and current updates on genitourinary (GU) malignancies. The upcoming 11th European Multidisciplinary Congress on Urological Cancers (EMUC19) will be no different. One of its...

Trial presentations to have “Guideline-changing potential”

“Onco-urology is a rapidly-evolving field. Next to classical systemic therapies such as androgen deprivation in prostate cancer or chemotherapy, immunotherapeutical approaches or newer, more potent antiandrogens are increasingly incorporated in the armamentarium of medical uro-oncologists,” says urologist Dr. Tobias...